Literature DB >> 25502807

The molecular mechanisms underlying the therapeutic resistance of cancer stem cells.

Jun-Kyum Kim1, Hee-Young Jeon, Hyunggee Kim.   

Abstract

Chemo-resistance and radio-resistance are a major cause of recurrence and progression of many cancers, regardless of improvements in therapies. Since cancer stem cells (CSCs) were identified as a rare population with the abilities of self-renewal; tumor initiation; aberrant differentiation, which contributes to tumor heterogeneity; and resistance to anticancer therapeutics, they have been considered a major cause of tumor recurrence post-therapy and a primary therapeutic target in relapse prevention. A number of studies have demonstrated the mechanisms underlying chemo-resistance and radio-resistance of CSCs. In this review, we describe intrinsic and extrinsic factors underlying CSC chemo-resistance and radio-resistance. The intrinsic factors regulate CSC signaling pathways involved in stem cell signaling, anti-apoptotic pathways, ABC transporter expression, and DNA damage repair systems. The extrinsic factors include the resistance mechanisms resulting from the interactions between CSCs and the microenvironment composed of vessels, fibroblasts, immune cells, extracellular matrix, and diverse soluble factors. Furthermore, we introduce diverse therapeutic agents used in experimental or clinical trials to target CSCs. Understanding how CSCs acquire resistance to anticancer therapeutics will give us opportunity to develop improved therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25502807     DOI: 10.1007/s12272-014-0531-1

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  21 in total

1.  Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.

Authors:  Oğuzhan Karaosmanoğlu; Sreeparna Banerjee; Hülya Sivas
Journal:  Cell Oncol (Dordr)       Date:  2018-06-01       Impact factor: 6.730

Review 2.  Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond.

Authors:  Ruya Zhao; Rayan Kaakati; Andrew K Lee; Xinjian Liu; Fang Li; Chuan-Yuan Li
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

Review 3.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.

Authors:  Joleen M Hubbard; Axel Grothey
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 5.  Resistance to Cell Death and Its Modulation in Cancer Stem Cells.

Authors:  Ahmad R Safa
Journal:  Crit Rev Oncog       Date:  2016

6.  Spheres from cervical cancer cells display stemness and cancer drug resistance.

Authors:  Huan Liu; Haijuan Wang; Chunxiao Li; Tingting Zhang; Xiting Meng; Ying Zhang; Haili Qian
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

Review 7.  The Clinical Impact of Cancer Stem Cells.

Authors:  Justin Lathia; Huiping Liu; Daniela Matei
Journal:  Oncologist       Date:  2019-12-17

8.  Cell membrane permeability and defective G2/M block as factors potentially contributing to increased cell chemosensitivity. SeAx cell line as an example.

Authors:  Edyta Biskup; Omid Niazi; Vibeke Pless
Journal:  Biochem Biophys Rep       Date:  2021-05-08

9.  Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.

Authors:  Wei Xia; Chung Mau Lo; Randy Y C Poon; Tan To Cheung; Albert C Y Chan; Lin Chen; Sitian Yang; George S W Tsao; Xiao Qi Wang
Journal:  Oncotarget       Date:  2017-06-13

10.  Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes.

Authors:  Rui Yang; Li Y An; Qin F Miao; Feng M Li; Yong Han; Hui X Wang; Dang P Liu; Rong Chen; Sha Q Tang
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.